What is the safety and clinical effectiveness, acceptability and cost effectiveness of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by ambulatory care nurses for people with multiple sclerosis?

What is the safety and clinical effectiveness, acceptability and cost effectiveness of flexible delivery of natalizumab (Tysabri (Registered Trademark)) by ambulatory care nurses for people with multiple sclerosis?

Not yet recruiting

Phase of Trial:
Phase III

Latest Information Update:04 Apr 2017

At a glance

Drugs
Natalizumab (Primary)

Indications
Multiple sclerosis

Focus
Adverse reactions

Most Recent Events

30 Jun 2016
New trial record

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login
with a username/password associated to an account with a valid subscription